Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence study of Odefsey as compared to Genvoya and Edurant

Trial Profile

Bioequivalence study of Odefsey as compared to Genvoya and Edurant

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Rilpivirine
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 23 Jun 2016 According to a Gilead Sciences media release, the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.
    • 29 Apr 2016 According to a Gilead Sciences media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted positive opinion on the MAA for Odefsey for the treatment of HIV-1 infection in adults and adolescents. The MAA was supported by data from this trial.
    • 07 Mar 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top